Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 7/20 | 0.51 |
| ▸ | USP2 | O75604 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.43 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3272253 | 0.88 | FAAH (0.62) | FAAHSMN1; SMN2RPS6KA3KARS1TRPV1 | |
| SCHEMBL3275452 | 0.85 | TRPV1 (0.52) | FAAHUSP2CYP1A2MAPK1CYP2C19 | |
| SCHEMBL3269311 | 0.83 | FAAH (0.65) | FAAHUSP2CYP1A2MAPK1CYP2C19 | |
| SCHEMBL3274880 | 0.81 | FAAH (0.57) | FAAHMAPK1TRPV1GSK3BALDH1A1 | |
| SCHEMBL3269282 | 0.81 | POLB (0.60) | FAAHUSP2CYP1A2SMN1; SMN2MAPK1 | |
| SCHEMBL3267735 | 0.79 | CSNK1D (0.47) | FAAHUSP2CYP1A2SMN1; SMN2MAPK1 | |
| SCHEMBL3274874 | 0.76 | DGAT1 (0.45) | FAAHUSP2CYP1A2SMN1; SMN2MAPK1 | |
| SCHEMBL3269574 | 0.76 | DGAT1 (0.44) | FAAHUSP2CYP1A2SMN1; SMN2MAPK1 | |
| SCHEMBL3268499 | 0.74 | FAAH (0.54) | FAAHTRPV1MAPTALDH1A1 | |
| SCHEMBL3269596 | 0.73 | FAAH (0.61) | FAAHUSP2CYP1A2MAPK1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234389-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20100234389-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20100234389-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-16 | — | — | US | disclosed |
| EP-2199282-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-06-23 | — | — | EP | disclosed |
| US-20090163508-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-25 | — | — | US | disclosed |
| US-20090163508-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-25 | — | — | US | disclosed |
| US-20090163508-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234389-A1 | AMIDE COMPOUND | FAAH, FAAH2, NAAA | FAAH 1/4885USP2 793/4885CYP1A2 728/4885 |
| US-20090163508-A1 | AMIDE COMPOUND | FAAH, FAAH2, NAAA | FAAH 1/4885USP2 793/4885CYP1A2 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.